Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

CJC-1295 vs Sermorelin: Key Differences Compared

CJC-1295 Sermorelin Class / subtitle Long-acting GHRH analog Short-acting GHRH(1-29) analog Research status In clinical trials FDA-approved Categories Growth Hormone Growth Hormone Primary targets GHRH receptor GHRH receptor Half-life ≈6–8 days with DAC; ≈30 minutes without DAC (Mod GRF 1-29) ≈10–20 minutes Sequence Modified GRF(1-29) tetrasubstituted analog with a Drug Affinity Complex (DAC) linker GRF(1-29)-NH2 (first 29 residues of human GHRH) Molecular formula C152H252N44O42 C149H246N44O42S Molecular weight ≈3647.2 g/mol (with DAC) 3357.9 g/mol CAS number 863288-34-0 86168-78-7 Routes (research) subcutaneous subcutaneous

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

CJC-1295 Sermorelin Class / subtitle Long-acting GHRH analog Short-acting GHRH(1-29) analog Research status In clinical trials FDA-approved Categories Growth Hormone Growth Hormone Primary targets GHRH receptor GHRH receptor Half-life ≈6–8 days with DAC; ≈30 minutes without DAC (Mod GRF 1-29) ≈10–20 minutes Sequence Modified GRF(1-29) tetrasubstituted analog with a Drug Affinity Complex (DAC) linker GRF(1-29)-NH2 (first 29 residues of human GHRH) Molecular formula C152H252N44O42 C149H246N44O42S Molecular weight ≈3647.2 g/mol (with DAC) 3357.9 g/mol CAS number 863288-34-0 86168-78-7 Routes (research) subcutaneous subcutaneous

Connected topics

Follow this recovery question